Affiliation:
1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Abstract
Introduction. It is generally accepted that dedifferentiated chondrosarcomas are a result of transformation of low-grade (grade I and II) malignant chondrosarcomas into sarcoma with marked signs of cellular and tissue anaplasia with more aggressive clinical progression. Morphological examination of dedifferentiated chondrosarcomas allows to detect presence of pre-existent low-grade malignant chondrosarcoma tissue. Dedifferentiated chondrosarcomas comprise about 10 % of all chondrosarcomas. Most frequently, this tumor is located in the femur, pelvic bones, and humerus. A common clinical complication of dedifferentiated chondrosarcomas is pathological fracture. This disease is characterized by more aggressive progression with unfavorable prognosis compared to conventional types of chondrosarcomas.Aim. To study in detail the data of laboratory, clinical, radiological and morphological examinations of patients with different chondrosarcoma types for refinement of the algorithm of dedifferentiated chondrosarcoma examination and diagnosis.Materials and methods. Between 2008 and 2022, data of 160 patients with chondrosarcomas of varying locations and differentiation were analyzed. Diagnosis of “cartilaginous tumor” was made in all patients after clinical and radiological exams, as well as preoperative biopsy. Diagnosis of “dedifferentiated chondrosarcoma” was made in 30 patients. Radiological exam included several methods (X-ray, X-ray computed tomography, and magnetic resonance imaging) and modes of patient examination. Morphological diagnosis included routine techniques of histological analysis with gentle decalcification and subsequent immunohistochemical (PD-L1, PU-1, CD8, CD20, Ki67, CD34) and genetic analyses (IDH1/IDH2).Results. Among 160 patients, preoperative biopsy verified the diagnosis of “dedifferentiated chondrosarcoma” only in 6 patients. In 4 patients, the possibility of chondrosarcoma transformation into poorly differentiated sarcoma of non-cartilaginous structure was suspected. At the stage of postoperative material examination, diagnosis of “dedifferentiated chondrosarcoma” was confirmed in 4 patients with suspicion of more malignant tumor transformation and newly made in 20 more patients. Female patients were a little more common (19/11). Mean patient age was 59 years. Pathological fracture at the preoperative stage was observed in 6 patients. In almost one third of the cases (36 %), decreased differentiation of chondrosarcoma compared to preoperative biopsy was observed. It is important for management of these patients that in approximately 13 % of chondrosarcoma cases, recurrence with decreased tumor differentiation is observed.Conclusion. Radical surgical resection remains the standard treatment of chondrosarcoma as the effectiveness of radio- and chemotherapy is limited though it remains important in dedifferentiated type of the disease. These circumstances lead to the use of tumor immunotherapy targeted at the search for potential use of the immune response for recognition and killing of various malignant cells including dedifferentiated chondrosarcoma. Consequently, a promising research direction is determination of the significance of tumor-associated macrophages, as well as tumor-infiltrating lymphocytes as antitumor factors and biomarkers affecting clinical and morphological characteristics of oncological diseases.
Publisher
Publishing House ABV Press
Reference22 articles.
1. Inwards S., Hohendorm P.C.W. Dedifferentiated chondrosarcoma. In: World Health Organization Classification of Tumors. Pathology and genetics of tumors of soft tissue and bone. Ed. by C.D.M. Fletcher, J.A. Bridge, P.C.W. Hogendorm, F. Mertens. IARC Press, Lyon, 2002. Pp. 388–389.
2. Bovée J.V., Cleton-Jansen A.M., Rosenberg C. et al. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implication for its histogenesis. J Pathol 1999;189(4):454–62. DOI: 10.1002/(SICI)1096-9896(199912)189:4<454::AID-PATH467>3.0.CO;2-N
3. Ropke M., Boltze C., Neumann H.W. et al. Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma, Pathol Res Pract 2003;199(6):437–44. DOI: 10.1078/0344-0338-00443
4. Amary M.F., Bacsi K., Maggiani F. et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumors. J Pathol 2011;224(3):334–43. DOI: 10.1002/path.2913
5. Vigorita V.J. Orthopaedic Pathology, Lippincott Williams and Wilkins, 2008. Pp. 421–422.